[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579157":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":35,"locations":34,"responsibleParty":42,"collaborators":34,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":56,"maxAge":34,"enrollmentInfo":57,"targetDuration":34,"studyType":60,"phases":61,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":71,"whyStopped":34,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":34},{"fullName":5,"class":6},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Calcium Receiving","EXPERIMENTAL","Patients will receive standard care according to the Ontario MHP with calcium gluconate administration after every 4 units of RBCs given during the MHP.",[13],"Drug: calcium gluconate",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Comparator","PLACEBO_COMPARATOR","Patients will receive standard care according to the Ontario MHP with saline placebo administration after every 4 units of RBCs given during the MHP.",[19],"Drug: Control: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","calcium gluconate","3g IV or IO calcium gluconate.",[9],[27],"Calcium",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Control: Placebo","3g of IV or IO saline placebo.",[15],[33],"saline",null,[36],{"name":37,"role":38,"phone":39,"phoneExt":40,"email":41},"Ian Ball, MD","CONTACT","519-685-8500","71513","Ian.Ball@lhsc.on.ca",{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":46,"oldNameTitle":34,"oldOrganization":34},"PRINCIPAL_INVESTIGATOR","Ian Ball","Associate Professor, Department of Medicine","London Health Sciences Centre","100579157","phase-2-calcium-administration-in-life-saving-management-during-massive-hemorrhage-100579157",false,"NCT06820645","Calcium Administration in Life-saving Management During Massive Hemorrhage","CALM: Calcium Administration in Life-saving Management of Trauma Patients Undergoing Massive Hemorrhage Protocol: a Single Centre Feasibility Study","CALM","Inclusion Criteria:\n\n* Adult trauma patients undergoing the MHP at Victoria Hospital, London, Ontario\n\nExclusion Criteria:\n\n* Under the age of 18\n* Pregnant","ALL","18 Years",{"count":58,"type":59},81,"ESTIMATED","INTERVENTIONAL",[62,63],"PHASE2","PHASE3","This study evaluates the feasibility of conducting a larger study on the impact of treating massive hemorrhage with calcium in trauma patients. Patients undergoing the Massive Hemorrhage Protocol (MHP) will be randomly assigned to receive either calcium gluconate or placebo drug after every 4 packs of units of RBCs received during the MHP.",[66,67,68],"Massive Hemorrhage","Trauma","Hypocalcemia",[27,70],"Massive Hemorrhage Protocol","NOT_YET_RECRUITING","2025-02-05",{"date":74,"type":75},"2025-02-11","ACTUAL",{"date":77,"type":59},"2025-05-01",{"date":79,"type":59},"2026-05",{"name":5,"class":6}]